Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy

Women with breast cancer who receive adjuvant therapy are at risk for developing therapy-related myelodysplastic syndrome (MDS) or AML (tMDS/AML). Patients with tMDS/AML are often referred for consideration of allogeneic hematopoietic SCT (HSCT). However, the outcomes of HSCT in such patients have n...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Armand, P, Kim, HT, Mayer, E, Cutler, CS, Ho, VT, Koreth, J, Alyea, EP, Antin, JH, Soiffer, RJ
Médium: Artigo
Jazyk:Inglês
Vydáno: 2010
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2889243/
https://ncbi.nlm.nih.gov/pubmed/20154738
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bmt.2010.20
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky